FDA Removed 12 Peptides From Category 2: What It Means
On April 15, 2026 the FDA moved 12 peptides off Category 2 of the 503A bulks list. Here is what the regulatory change does and does not do.
FDA Removed 12 Peptides From Category 2: What It Actually Means **No. The FDA's April 2026 action does not make BPC-157, TB-500, or the other named peptides legal to compound. On April 15, 2026, the FDA gave notice that it would remove 12 peptide bulk substances from Category 2 of the 503A bulks list, the bucket flagged as posing a significant safety risk. Removal from Category 2 does NOT add these peptides to the 503A bulks list, and it does NOT move them to Category 1. It only strips the safety-risk flag pending further review. The action, tied to docket FDA-2025-N-6895, routes the peptides toward Pharmacy Compounding Advisory Committee (PCAC) consideration, whose recommendations are advisory and non-binding. Until a peptide is formally placed on the 503A bulks list, compounding it from bulk substance is not authorized simply because it left Category 2. This article reports the regulatory status only. For any decision about your own protocol, defer to your prescriber or provider.** The headline that circulated in April 2026 was widely misread. Many summaries framed the move as the FDA "approving" or "legalizing" a list of popular research peptides. That is not what happened. The agency reorganized how these substances sit within a regulatory evaluation process, and the practical bottom line for compounding did not change in the way the headlines implied. Below, we walk through what the 503A bulks list is, what Category 2 means, which peptides are involved, and why the distinction between leaving Category 2 and joining the list matters so much. The goal is to help you understand the landscape and organize your own health data, not to tell you what to take or where to source anything.
The Short Version: Status as of Mid-2026
Here is the regulatory picture in plain terms:
This is a developing regulatory matter, and the dates and findings here reflect the public record. Nothing in this article is medical guidance.
The 12 Peptides Involved
The 12 peptide bulk substances named in the April 2026 notice are listed below. Several of these are familiar to anyone following the research-peptide space. None of them is an FDA-approved drug.
|---|---|
To be explicit for compliance and clarity: every substance in this table is investigational or unapproved. None has gone through the FDA's approval process for safety, efficacy, and manufacturing quality the way an approved drug has. Treating any of these as a vetted, approvable product because it left Category 2 is exactly the misreading this article aims to correct.
What the 503A Bulks List and Category 2 Actually Are
The 503A bulks list comes from section 503A of the Federal Food, Drug, and Cosmetic Act. It is the list of bulk drug substances that traditional compounding pharmacies are permitted to use when there is no applicable monograph and the substance is not a component of an FDA-approved drug. If a bulk substance is not on the list and does not otherwise qualify, a 503A pharmacy is not authorized to compound from it.
While the FDA evaluates nominated substances for the list, it sorts them into categories. The two that matter for this story are:
The key point is that neither category is the list itself. Category 1 and Category 2 are interim sorting buckets for substances that are being evaluated. Being in Category 1 is not the same as being on the 503A bulks list, and leaving Category 2 does not place a substance anywhere except back into the general pool of substances still awaiting a formal decision.
Why "Removed From Category 2" Is Not "Now Legal"
This is the crux of the entire story, so it is worth stating carefully. When the FDA removed these 12 peptides from Category 2, it lifted the significant-safety-risk flag. That is a meaningful procedural step, but it is not a green light. Here is the contrast that the headlines collapsed.
|---|---|
Reading down that table, you can see how far "removed from Category 2" sits from "authorized to compound." A substance has to travel through advisory review and formal rulemaking before it lands on the 503A bulks list, and only the last row, an approved drug, reflects full FDA review. As the source analyses put it, removal from Category 2 strips the safety flag pending review and nothing more. Until a peptide is formally placed on the 503A bulks list, compounding it from bulk substance is not authorized simply because it left Category 2.
The Pathway and the Timeline
So where do these 12 peptides go from here? The April 2026 action, tied to docket FDA-2025-N-6895, routes them toward the Pharmacy Compounding Advisory Committee. PCAC is an advisory body that reviews nominated bulk substances and makes recommendations to the FDA about whether they belong on the 503A bulks list.
Two features of this pathway are easy to overlook and important to understand:
In other words, the April action is closer to the start of a multi-step evaluation than to a conclusion. People reading "the FDA removed these from the safety-risk category" as a finish line have the sequence backwards. It is a procedural waypoint, with advisory review and a potentially multi-year rulemaking process still ahead.
What This Means If You Are Following These Peptides
If you have been tracking any of these 12 peptides, the most important takeaway is to keep your expectations aligned with the actual regulatory record rather than the headlines. None of these substances became an approved drug in April 2026, and none became authorized for compounding by leaving Category 2. The status that changed is narrow and procedural.
For anyone working with a clinician on any health protocol, the appropriate next step for clinical questions is to talk with the prescriber or provider who manages your care. Whether a given compound is appropriate, available through a lawful channel, or worth discussing at all is a clinician-directed question that depends on your individual situation, which only your provider can assess. This article cannot and does not offer dosing guidance, and it does not point to sources. For unapproved compounds, no responsible resource should.
What this article will not do is suggest that the regulatory change opened a door to obtain or use any of these peptides. The door the headlines described does not exist. The constructive move, regardless of how any individual peptide evaluation eventually lands, is to keep a clean, organized record of whatever you are tracking so that any provider conversation is grounded in good data. You can browse plain-language overviews in the [peptide library](/peptides) or the [best peptides](/best-peptides) explainer to understand what these compounds are, without treating any overview as a recommendation.
What to Track: Biomarkers Worth Monitoring
Whether you are simply following this regulatory story or working with a provider on a broader health picture, the value of a clean longitudinal record does not change. People who track their health alongside their providers commonly keep an eye on metabolic, hormonal, and safety-relevant markers over time. The following are biomarkers researchers and clinicians frequently discuss in general health-tracking contexts. None of this is a recommendation to test or treat. It is a list of what is commonly tracked so you can organize your own data and discuss it with your provider.
Tracking these consistently, rather than as scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot. A trend line tells a story. You can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test.
[Track your protocol and labs in one place with MyProtocolStack.](/auth/login?mode=signup)
How This Fits the Broader 2026 Regulatory Picture
The April 2026 Category 2 action does not stand alone. 2026 has been an active year for peptide and compounding regulation, with multiple substances seeing their status reconsidered as the FDA works through its bulk-substance evaluations and as separate decisions move through the 503B outsourcing-facility framework. The throughline is consistent: the agency is methodically sorting which substances clear its evaluation bars and which do not, and procedural waypoints in that process are routinely mistaken for final answers.
For people tracking their health seriously, the practical takeaway is the same regardless of which way any individual decision lands. Keep your records clean and provider-ready, read regulatory headlines against the actual public record, and treat unapproved compounds as exactly that. You can explore structured overviews of individual compounds in the [peptide library](/peptides) whenever you want context on what a given peptide is and is not.
Frequently Asked Questions
Does the FDA removing 12 peptides from Category 2 make them legal to compound?
No. On April 15, 2026, the FDA gave notice it would remove 12 peptides, including BPC-157 and TB-500, from Category 2 of the 503A bulks list, which lifts the significant-safety-risk flag pending review. Removal from Category 2 does not add these peptides to the 503A bulks list and does not move them to Category 1. Until a peptide is formally placed on the 503A bulks list, compounding it from bulk substance is not authorized simply because it left Category 2.
Which 12 peptides were removed from Category 2?
The 12 peptide bulk substances named in the April 2026 notice are BPC-157, TB-500, MOTS-c, KPV, DSIP (emideltide), Epitalon, Semax, injectable GHK-Cu, LL-37, DiHexa, Melanotan II, and PEG-MGF. None of these is an FDA-approved drug, and the Category 2 action did not change that.
What is the difference between Category 1, Category 2, and the 503A bulks list?
Category 1 and Category 2 are interim sorting buckets the FDA uses while it evaluates nominated bulk substances. Category 2 flags substances that may pose a significant safety risk, while Category 1 covers substances under review without that flag. The 503A bulks list itself is the separate, final list of substances that traditional compounding pharmacies are actually permitted to compound from. Being in either category is not the same as being on the list.
What happens to these peptides next?
The action, tied to docket FDA-2025-N-6895, routes the 12 peptides toward Pharmacy Compounding Advisory Committee (PCAC) consideration. PCAC recommendations are advisory and non-binding, so the FDA is not obligated to follow them. Even where the agency decides to add a substance to the 503A bulks list, the formal rulemaking process can take 12 to 24 months.
I am interested in one of these peptides. What should I do?
Talk with the prescriber or provider who manages your care. Whether any of these compounds is appropriate or available through a lawful channel is a clinician-directed question that depends on your individual situation. MyProtocolStack does not provide medical advice and cannot tell you what to take or where to obtain it. What you can do on your own is keep an organized record of the markers you track over time, so any provider conversation is grounded in good data.
Sources
1. Orrick, "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings," April 2026. https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
2. FDA Law Blog, "FDA's Peptide Rally: What Compounders and Industry Need to Know (Post 1 of 2)," April 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
3. Buchanan Ingersoll & Rooney, "Peptides at the Crossroads: FDA Tightens the Line as Category 2 Pushes Toward Category 1." https://www.bipc.com/peptides-at-the-crossroads-fda-tightens-the-line-as-category-2-pushes-toward-category-1
4. U.S. Food and Drug Administration, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →